Sectors
CNTA
Centessa Pharmaceuticals plc
40.50
1 x 29.07
1 x 51.57
bid
ask
+
0.32
0.80%
04:00 PM
timesize
| Ytd | 61.94% | |
| 1y | 208.45% |
40.00
day range
40.56
12.78
52 week range
40.56
| Open | 40.09 | Prev Close | 40.18 | Low | 40.00 | High | 40.56 | Mkt Cap | 6.27B |
| Vol | 0.00 | Avg Vol | 2.94M | EPS | -1.79 | P/E | -22.63 | Forward P/E | -22.75 |
| Beta | 1.11 | Short Ratio | 1.35 | Inst. Own | 96.93% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-14 | 50-d Avg | 39.71 | 200-d Avg | 29.33 | 1yr Est | 40.25 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-11 | 2026-06 | -0.4 | N/A | N/A | N/A |
| 2026-05-05 | 2026-03 | -0.38 | -0.52 | -0.14 | -36.84% |
| 2026-03-31 | 2025-12 | -0.37 | -0.48 | -0.11 | -29.23% |
| 2025-11-05 | 2025-09 | -0.39 | -0.41 | -0.02 | -5.13% |
| 2025-08-12 | 2025-06 | -0.35 | -0.38 | -0.03 | -8.57% |
| 2025-05-14 | 2025-03 | -0.35 | -0.2 | 0.15 | 42.86% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-04-20 | Wells Fargo | Downgrade | Overweight | Equal-Weight |
| 2026-04-02 | Guggenheim | Downgrade | Buy | Neutral |
| 2026-04-01 | Leerink Partners | Downgrade | Outperform | Market Perform |
| 2026-03-31 | Wolfe Research | Downgrade | Outperform | Peer Perform |
| 2026-03-31 | Needham | Downgrade | Buy | Hold |
| 2026-02-24 | Wolfe Research | Upgrade | Outperform |
Profile
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also engages in the development of ORX142 which is in Phase I clinical trial for the treatment of neurological and neurodegenerative disorders; ORX489 which is in Phase I clinical trial for the treatment of neuropsychiatric disorders; and LockBody, an early-stage immuno-oncology program technology platform. The company was incorporated in 2020 and is headquartered in Altrincham, the United Kingdom.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-02-01 | ACCARDI MARIO ALBERTO | Chief Executive Officer | 243.89K | Stock Award(Grant) |
| 2026-03-25 | ANDERSON KAREN M | Officer | 62.09K | Sale |
| 2026-02-01 | BUSH TIA L | Chief Technology Officer | 147.95K | Stock Award(Grant) |
| 2025-03-16 | CHAO DAVID M | Officer | 225.01K | Sale |
| 2026-02-01 | CROWLEY JOHN JOSEPH CPA | Chief Financial Officer | 45.00K | Stock Award(Grant) |
| 2025-05-15 | GOYAL ARJUN | Director | 0.00 | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Medicxi Ventures Management (Jersey) Ltd | 19.96M | 0.00 | 12.90% |
| 2026-03-30 | venBio Select Advisor LLC | 11.43M | 0.00 | 7.39% |
| 2026-03-30 | Index Venture Life Associates VI Ltd | 9.96M | 0.00 | 6.44% |
| 2026-03-30 | Adage Capital Partners Gp LLC | 8.93M | 0.00 | 5.77% |
| 2026-03-30 | Pentwater Capital Management LP | 8.17M | 0.00 | 5.28% |
| 2026-03-30 | FMR Inc | 6.85M | 0.00 | 4.43% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | American Funds SMALLCAP World A | 4.42M | 0.00 | 2.86% |
| 2026-04-29 | Fidelity Contrafund | 1.32M | 0.00 | 0.85% |
| 2026-03-30 | Federated Hermes Kaufmann Growth | 1.24M | 0.00 | 0.80% |
| 2026-03-30 | Federated Hermes Kaufmann R | 1.24M | 0.00 | 0.80% |
| 2026-03-30 | Janus Henderson Triton D | 853.85K | 0.00 | 0.55% |
| 2026-03-30 | Janus Henderson US SMID Cap Growth | 853.85K | 0.00 | 0.55% |
Dividend
| Dividend | Date |
|---|---|
| 38 | 2026-06-24 |